Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Subclonal evolution and cytogenetic aberrations in myeloma

Jill Corre • 13 May 2022
COMy 2022
Multiple Myeloma

Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, briefly discusses subclonal evolution in multiple myeloma, and the importance of identifying high-risk cytogenetic markers at diagnosis. Dr Corre explains how gain of chromosome 1q (+1q) is better detected by single-cell analysis and the importance of identifying high-risk markers such as (+1q) or del(17p) at an earlier stage to improve patient prognosis. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Jill Corre

Updates in the genomics of SMM & multiple myeloma
Francesco Maura et al. • 15 Apr 2023
1:57
Using molecular abnormalities for risk stratification in multiple myeloma at the time of diagnosis
Jill Corre • 12 May 2023
2:20
Novel technologies and the prognostic value of identifying subclones in myeloma
Jill Corre • 12 May 2023
2:02
The impact of heterogeneity on outcomes in multiple myeloma
Jill Corre • 30 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals